Navigation Links
aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
Date:8/14/2013

SAN DIEGO, Aug. 14, 2013 /PRNewswire/ -- aTyr Pharma, an innovative medical therapeutics enterprise, announced today that the United States Patent and Trademark Office (USPTO) has granted two patents that protect therapeutic and pharmaceutical compositions for two novel Physiocrines. Physiocrines are naturally occurring human proteins that possess novel in vivo biological activity as extracellular signaling molecules in known pathways relevant to developing protein therapeutics for a range of diseases. 

(Logo: http://photos.prnewswire.com/prnh/20120809/MM55538LOGO)

"Physiocrines are a new class and a significant source of novel proteins to treat many different types of diseases.  We have dedicated ourselves to meticulously exploring and validating the biology associated with Physiocrines and developing an emerging pipeline of therapeutics," said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma.  "Building this patent estate also reflects our business model and leverages our research efforts, including those accomplished at Pangu BioPharma, our subsidiary in Hong Kong that is a collaboration with the Hong Kong University of Science and Technology and has received research grants from the Hong Kong Innovation and Technology Commission."

Dr. Mendlein continued, "From our explorations, we have established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics so that we can develop meaningful medicines that can benefit patients who face grave diseases."

Physiocrines are produced from ancient genes, aminoacyl tRNA synthetases, an intercellular gene family in protein synthesis. Overlooked by genomic discovery efforts, Physiocrines are naturally occurring proteins that modulate extracellular signaling pathways in a variety of physiological processes. These endogenous human proteins act through a variety of receptor classes via mechanisms distinct from current pharmaceuticals and have potential applications in a number of therapeutic areas. aTyr is focused on using Physiocrines to generate therapeutic physiologic responses in immune system disorders, including acute and chronic inflammation and other forms of disordered immunity.

The two patents are Patent Nos. US 8,404,242 and US 8,404,471 and are entitled, "Compositions and methods comprising histidyl-TRNA synthetase splice variants having non-canonical biological activities," and "Compositions and methods comprising glycyl-TRNA synthetase splice variants having non-canonical biological activities," respectively.  The patents cover therapeutically relevant compositions including fragments and alternatively spliced product forms of the full-length gene which display enhanced biological activity and pharmaceutical properties compared to the full length proteins.

About Physiocrines

Physiocrines act as extracellular signaling molecules to orchestrate cellular homeostasis in response to stress. Physiocrines are naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and the resolution of inflammation. As potent endogenous modulators of inflammation, Physiocrines offer the opportunity for modulating biological pathways through new naturally occurring mechanisms, many of which have multiple therapeutic advantages, including improved selectivity, efficacy and reduced side effect profiles compared to many existing anti-inflammatory therapeutics.

About aTyr Pharma

aTyr Pharma has developed an extensive pipeline of future therapeutic products based on Physiocrine biology. aTyr has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr's key programs are currently focused on rare immunomodulation disorders in the areas of inflammation and immunity. These diseases are serious potentially life threatening autoimmune conditions, for which there are currently no effective, safe, long term treatments. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. Announces Positive Results for Ampion in Osteoarthritis of the Knee Clinical Trial
2. aTyr Pharma Expands Executive Leadership Team to Support Development of New Therapeutics Based on Physiocrine Biology
3. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
4. 200 Pharma Customers to Attend ChemOutsourcing September 17-19, 2013, NJ, USA
5. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
6. Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc.
7. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
8. AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
9. PipelineRx Announces Telepharmacy Contract with GNYHA Services
10. Emdeon Continues Focus on Patient-Centered Healthcare Solutions; Renews Chain Drug Consortium Contract for Multiple Pharmacy Solutions
11. ANI Pharmaceuticals Announces an Agreement for the Development and Marketing of an Oral Soft Gel Prescription Product with Sofgen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan. 17, 2017  Maureen L. ... announces the addition of 6 senior sales leaders ... TubeClear® System.  These sales leaders were formerly part ... medical device company. Repeatedly recognized for their performance, ... customer expectations and establishing relationships with key customer ...
(Date:1/17/2017)... , January 17, 2017 Transparency Market ... Acid, Benzoic Acid, Sodium Benzoate, Benzyl Alcohol and Others) Market - ... to the report, the global benzaldehyde derivative market was ... reach US$ 2.14 Bn by 2024, expanding at a CAGR of ... ...
(Date:1/16/2017)... -- Research and Markets has announced the addition of ... their offering. ... Global multiple myeloma drugs market to grow at a CAGR of ... the present scenario and the growth prospects of the global multiple ... report considers the revenue generated from the sales of branded and ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, ... highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, ... this elite group of providers. , Produced by Zeltiq, CoolSculpting is approved by ...
(Date:1/17/2017)... TEXAS (PRWEB) , ... January 17, 2017 , ... ... provider, today announced its partnership with Sigfox in the U.S.A. to ... cities nationwide including new offerings on large-scale environmental sensor deployments such as ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... eliminate cyber threats in real-time, today announced a strategic partnership with TechLab ... Malaysia. Joining other Seceon partners, TechLab Security has become a strategic partner and ...
(Date:1/17/2017)... ... 2017 , ... Today, FloSports , a global leader in live digital ... part of a long-term extension of their media partnership. The partnership, which began in ... the sport’s premier events exclusively on FloWrestling.com as well as usage of the FloArena ...
(Date:1/16/2017)... ... January 16, 2017 , ... Gym Source, America’s leading retailer of premium residential ... Hanover, New Jersey. , “We are elated to be opening this new showroom,” explains ... designed to give clients a seamless and motivating shopping experience.” , Every fitness journey ...
Breaking Medicine News(10 mins):